Mah Sing gets approval to market gloves in US


“With the updated 510(k) clearance, Mah Sing Healthcare will be able to market medical-grade examination gloves which can be used in the handling or preparation of chemotherapeutic drugs in the US. “This will enable big medical players in the US to obtain gloves from Mah Sing Healthcare as their existing suppliers also carry the chemotherapy protection claim,” the group said in a statement yesterday.

PETALING JAYA: Mah Sing Group Bhd’s indirectly owned unit, Mah Sing Healthcare Sdn Bhd, has received the 510(k) premarket notification clearance to market its nitrile examination gloves and tested for use with chemotherapy drugs from the United States Food and Drug Administration (FDA).

“With the updated 510(k) clearance, Mah Sing Healthcare will be able to market medical-grade examination gloves which can be used in the handling or preparation of chemotherapeutic drugs in the US.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Mah Sing , healthcare , gloves , approval , U.S. ,

   

Next In Business News

Keyfield issues maiden RM200mil sukuk wakalah
Electricity tariff to rise by 14%�from�July�2025
Ringgit strengthens against US dollar as rising oil prices lift sentiment
MYMBN faces temporary suspension of bird’s nest exports to China
TNB shortlisted to develop 500MW solar plant in Kedah under LSS5
CCK Consolidated declares special dividend of 5.0 sen
Santa Claus rally extends on Bursa Malaysia
Alibaba, E-Mart to create US$4bil e-commerce JV in Korea
Oil prices inch up on hopes for more China stimulus
Gold gains on geopolitical turmoil; Fed, Trump's 2025 policies in focus

Others Also Read